Cefodizime: Broad-Spectrum Cephalosporin for Gram-Positive and Gram-Negative Infection Research

Executive Summary: Cefodizime (APExBIO, SKU BA1050) is a third-generation cephalosporin antibiotic with broad-spectrum activity against both Gram-positive and Gram-negative bacterial pathogens, including methicillin-sensitive Staphylococcus aureus and Escherichia coli (MIC₉₀ = 0.40 mg/L) (Huy et al., 2020). Its action is mediated by inhibition of bacterial penicillin-binding proteins (PBPs), particularly PBPs 1A/B, 2, and 3 of E. coli, disrupting cell wall synthesis [Product]. Cefodizime exhibits β-lactamase stability and immunomodulatory effects, enhancing phagocytic cell function (Cefodizime: Broad Spectrum Antibiotic for Infectious Disease Models). It is primarily excreted renally and is ineffective against Pseudomonas aeruginosa and extended-spectrum β-lactamase (ESBL)-producing strains. The compound is supplied as a solid, soluble in DMSO at ≥51.1 mg/mL for research use only.

Biological Rationale

Cefodizime addresses the need for broad-spectrum antibiotics in experimental models of infectious diseases and antimicrobial resistance. Antimicrobial resistance (AMR) is an escalating public health threat, as demonstrated by high rates of multidrug-resistant (MDR) E. coli in urban rodents, with 23.7% (14/59) of isolates showing cefodizime resistance (Huy et al., 2020, Table 2). The drug’s efficacy against a range of Gram-positive bacteria (e.g., Streptococcus spp., methicillin-sensitive S. aureus) and Gram-negative species (e.g., Enterobacteriaceae, Haemophilus influenzae, Neisseria spp.) supports its use in both respiratory and urinary tract infection models. Its β-lactamase stability enables sustained activity in environments where resistance is prevalent (Cefodizime in Antimicrobial Resistance Research: Next-Gen). Unlike many β-lactams, cefodizime also demonstrates immunomodulatory effects, enhancing phagocytic cell function and potentially improving host response (Cefodizime: Mechanistic Insights and Next-Gen Application).

Mechanism of Action of Cefodizime

Cefodizime inhibits bacterial cell wall synthesis by binding to and inactivating penicillin-binding proteins (PBPs), which are crucial for peptidoglycan cross-linking. It exhibits high affinity for PBPs 1A/B, 2, and 3 in Escherichia coli. Inhibition leads to cell lysis and bactericidal effects. Its β-lactam ring is resistant to many β-lactamases, conferring activity against β-lactamase-producing strains. Cefodizime also enhances the function of phagocytic cells, an immunomodulatory property not shared by all cephalosporins (Cefodizime: Broad Spectrum Antibiotic for Infectious Disease Models).

Evidence & Benchmarks

• MIC₉₀ for E. coli is 0.40 mg/L under standard aerobic conditions (37°C, Mueller-Hinton broth) (Huy et al., 2020).
• MIC₉₀ for Haemophilus influenzae is <0.01 mg/L; for Neisseria gonorrhoeae, 0.008–0.016 mg/L (same conditions) (APExBIO product data).
• Retains activity against methicillin-sensitive S. aureus and streptococci but is ineffective against MRSA and Pseudomonas aeruginosa (APExBIO).
• Demonstrated β-lactamase stability in clinical isolates and research models (Cefodizime in Translational Research: Mechanistic Insight).
• Renal excretion is 56–80% within 24 hours post-administration (adult humans, IV/IM dosing) (APExBIO).
• Resistance rates in urban rodent E. coli isolates: 23.7% (14/59) showed reduced susceptibility, highlighting environmental AMR risks (Huy et al., 2020).

For a deep dive into translational research strategies, see Cefodizime in Translational Infectious Disease Research, which provides a strategic framework beyond the pharmacological detail emphasized here.

Applications, Limits & Misconceptions

Cefodizime is optimized for use in microbiology research, particularly in antibacterial activity assays and in vivo infection models of both Gram-positive and Gram-negative pathogens. It is valuable in AMR surveillance studies, pharmacodynamic modeling, and immunomodulatory effect research. The compound’s DMSO solubility (≥51.1 mg/mL) allows for high-throughput screening workflows.

Common Pitfalls or Misconceptions

• Cefodizime is not effective against Pseudomonas aeruginosa or non-fermenting Gram-negative rods.
• It does not cover extended-spectrum β-lactamase (ESBL)-producing or methicillin-resistant S. aureus (MRSA) strains.
• It should not be used as a clinical therapy or in diagnostic procedures—research use only.
• Solubility is limited to DMSO; it is insoluble in ethanol and water, which may affect assay compatibility.
• Contraindicated in models simulating cephalosporin hypersensitivity or severe renal dysfunction.

This article extends the mechanistic focus presented in Cefodizime: Mechanistic Insights and Next-Gen Application by providing environmental resistance context and practical workflow parameters.

Workflow Integration & Parameters

• Formulation: Prepare stock at 10 mM in DMSO. Compound is a white to off-white solid, store at -20°C.
• Assay Compatibility: Use in microbiology assays (broth microdilution, agar diffusion) and animal infection models. DMSO content should not exceed 1–2% v/v in working solutions to avoid cytotoxicity.
• Dosing: For in vivo research, typical adult human equivalent dosing is 1–4 g/day (divided doses, IV/IM); adjust for animal models accordingly.
• Pharmacokinetics: Plasma protein binding is 81%; elimination half-life is 2–5 hours in humans. Renal excretion is primary route.
• Adverse Effects: Commonly observed reactions include gastrointestinal disturbance, cutaneous reactions, injection site irritation.

For further details on integrating cefodizime into resistance benchmarking, see Cefodizime in Antimicrobial Resistance Research: Next-Gen, which focuses on AMR phenotyping protocols, while this article emphasizes physicochemical and in vivo parameters.

Conclusion & Outlook

Cefodizime (APExBIO, BA1050) is a robust, broad-spectrum cephalosporin antibiotic, supporting high-fidelity infectious disease and AMR research. Its β-lactamase stability, immunomodulatory properties, and well-characterized pharmacokinetics make it an essential tool for modeling Gram-positive and Gram-negative infections. However, its limitations against ESBL-producing and Pseudomonas strains should be considered. Ongoing surveillance of environmental and clinical resistance, such as urban rodent studies, underlines the importance of continuous benchmarking in antibiotic research (Huy et al., 2020). For ordering details and technical specifications, see the Cefodizime BA1050 product page.